Arbutus Biopharma Cp (ABUS) Stock Price, Quote & News

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reaw...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 469 0914

Website: www.arbutusbio.com

Address:

701 Veterans Circle, Warminster, United States

jrothman22 Apr. 2 at 11:38 PM

$ABUS

2 · Reply

GABIRODZ01 Apr. 2 at 9:24 PM

$ABUS Taken from ChatGPT: • ✅ It increases odds of: • Settlement talks • Or major rulings

0 · Reply

DocPharm Apr. 2 at 8:40 PM

$ABUS $ROIV So Whitefort and Vanguard sold all of their ROIV shares Vivek sold about 1/2 of his, along with some other large firms and other execs… Intriguing to say the least

7 · Reply

FatedFish Apr. 2 at 8:31 PM

$ABUS Anybody got the screenshots of the transcript?

0 · Reply

DocPharm Apr. 2 at 8:12 PM

$ABUS Have a blessed Passover friends and foes

3 · Reply

mj6534 Apr. 2 at 7:25 PM

$ABUS trapped forever lol

0 · Reply

MyBrokenBus Apr. 2 at 6:50 PM

$ABUS Volume seems to have dried up. But all that volume the last two months to go... nowhere?

0 · Reply

Nile1 Apr. 2 at 6:49 PM

$ABUS let us go close green

0 · Reply

sheepmanct Apr. 2 at 9:20 AM

$ABUS For those that are interested in ROIV https://investor.roivant.com/news-releases/news-release-details/roivant-announces-expansion-brepocitinib-development-program-new/

1 · Reply

Grtgooglymoogly Apr. 1 at 8:20 PM

$ABUS vs Pfizer...A telephone status conference call yesterday, a letter to the judge from Abus/Genevant today......

2 · Reply

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Mar 3, 2026, 4:46 PM EST - 4 weeks ago

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

MRNA

Mar 3, 2026, 4:26 PM EST - 4 weeks ago

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

MRNA ROIV

Mar 3, 2026, 4:15 PM EST - 4 weeks ago

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

ROIV MRNA

Mar 3, 2026, 4:15 PM EST - 4 weeks ago

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

ROIV MRNA

Mar 3, 2026, 4:15 PM EST - 4 weeks ago

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

MRNA

Feb 3, 2026, 7:48 AM EST - 2 months ago

Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts

Nov 13, 2025, 7:30 AM EST - 5 months ago

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 7, 2025, 8:00 AM EDT - 6 months ago

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Aug 6, 2025, 7:30 AM EDT - 8 months ago

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 25, 2025, 7:30 AM EDT - 10 months ago

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

May 14, 2025, 7:30 AM EDT - 11 months ago

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 2:01 AM EDT - 11 months ago

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Apr 23, 2025, 2:01 AM EDT - 1 year ago

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Mar 27, 2025, 7:56 AM EDT - 1 year ago

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Mar 3, 2025, 9:15 AM EST - 1 year ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ROIV

Feb 25, 2025, 7:00 AM EST - 1 year ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Jan 30, 2025, 3:40 PM EST - 1 year ago

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

BUR CDZI

Jan 13, 2025, 7:30 AM EST - 1 year ago

Arbutus Provides 2025 Corporate and Financial Update

Jan 7, 2025, 7:56 AM EST - 1 year ago

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Dec 3, 2024, 8:00 AM EST - 1 year ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Nov 26, 2024, 7:30 AM EST - 1 year ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Nov 15, 2024, 11:02 AM EST - 1 year ago

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Nov 14, 2024, 7:30 AM EST - 1 year ago

Arbutus to Present at Jefferies London Healthcare Conference

Nov 6, 2024, 2:52 PM EST - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 15, 2024, 8:16 AM EDT - 1 year ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Two Upcoming Investor Conferences

Aug 1, 2024, 2:00 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 5, 2024, 5:29 AM EDT - 1 year ago

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Jun 6, 2024, 11:15 AM EDT - 1 year ago

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Jun 5, 2024, 2:30 AM EDT - 1 year ago

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Jun 3, 2024, 9:50 AM EDT - 1 year ago

Arbutus Distributors Ltd. News Release

May 29, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Participate in Jefferies Global Healthcare Conference

May 22, 2024, 2:00 AM EDT - 2 years ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 17, 2024, 9:00 AM EDT - 2 years ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

May 2, 2024, 1:15 PM EDT - 2 years ago

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

May 2, 2024, 7:30 AM EDT - 2 years ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:25 AM EDT - 2 years ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Apr 18, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 4, 2024, 8:30 AM EDT - 2 years ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Feb 29, 2024, 1:05 PM EST - 2 years ago

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 7:30 AM EST - 2 years ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 15, 2024, 7:30 AM EST - 2 years ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Jan 8, 2024, 7:30 AM EST - 2 years ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Nov 9, 2023, 4:01 PM EST - 2 years ago

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Nov 7, 2023, 11:06 AM EST - 2 years ago

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

jrothman22 Apr. 2 at 11:38 PM

$ABUS

2 · Reply

GABIRODZ01 Apr. 2 at 9:24 PM

$ABUS Taken from ChatGPT: • ✅ It increases odds of: • Settlement talks • Or major rulings

0 · Reply

DocPharm Apr. 2 at 8:40 PM

$ABUS $ROIV So Whitefort and Vanguard sold all of their ROIV shares Vivek sold about 1/2 of his, along with some other large firms and other execs… Intriguing to say the least

7 · Reply

FatedFish Apr. 2 at 8:31 PM

$ABUS Anybody got the screenshots of the transcript?

0 · Reply

DocPharm Apr. 2 at 8:12 PM

$ABUS Have a blessed Passover friends and foes

3 · Reply

mj6534 Apr. 2 at 7:25 PM

$ABUS trapped forever lol

0 · Reply

MyBrokenBus Apr. 2 at 6:50 PM

$ABUS Volume seems to have dried up. But all that volume the last two months to go... nowhere?

0 · Reply

Nile1 Apr. 2 at 6:49 PM

$ABUS let us go close green

0 · Reply

sheepmanct Apr. 2 at 9:20 AM

$ABUS For those that are interested in ROIV https://investor.roivant.com/news-releases/news-release-details/roivant-announces-expansion-brepocitinib-development-program-new/

1 · Reply

Grtgooglymoogly Apr. 1 at 8:20 PM

$ABUS vs Pfizer...A telephone status conference call yesterday, a letter to the judge from Abus/Genevant today......

2 · Reply

Heavey Apr. 1 at 8:18 PM

$ABUS glad it kept it’s head above water at the death.

0 · Reply

SpaceCityKid Apr. 1 at 5:24 PM

$ABUS The 6 month chart is looking more and more like a big inverted Head & Shoulder. We should see some action if we break > 4.80.

1 · Reply

tip2base Apr. 1 at 5:09 PM

$ABUS could this be the calm before the storm? Only 45k shares traded so far.

0 · Reply

bighodler Apr. 1 at 1:35 PM

$ABUS needs to do a merger... management should take note... look at $CYCN today... time to unlock the value of $ABUS

0 · Reply

StockosaurusTex Apr. 1 at 10:55 AM

$ABUS at this point it’s pretty clear this company does not need a C-Suite since they do nothing. Let’s save the money.

2 · Reply

invest5555 Apr. 1 at 2:40 AM

$ABUS Mar31 Telephone Conference

1 · Reply

CoinFlipTrader9 Mar. 31 at 11:03 PM

$ABUS review the 10-k again, Im trying to confirm the cycle time for the "timely appeal" to be submitted but not seeing what I thoight I saw - can amyone point me in the right direction?

2 · Reply

DocPharm Mar. 31 at 7:44 PM

$ABUS AB-101 update in very short order https://clinicaltrials.gov/study/NCT05960240 Will it come before the annual meeting notification/vote ? 🤔

0 · Reply

Alfalcon Mar. 31 at 4:45 PM

$ABUS Lindsey still evaluating! When is earnings call or is that pipe dream?

3 · Reply

GABIRODZ01 Mar. 31 at 4:06 PM

$ABUS Has anyone had experience with DealForma for tracking merging and acquisition Big Pharma companies?

0 · Reply

renoH4 Mar. 31 at 2:39 PM

$ABUS If 300 - 400 % IS Not enough you should buy Outcorp Silber & Gold, the risc IS Higher but 500 - 1000 % could be possible , WHO knows...🤩

1 · Reply

GABIRODZ01 Mar. 31 at 2:05 PM

$ABUS Maybe at the end of April on Earnings Report, we could expect a little price bump? Just a couple of minutes on the $4.85 area, maybe? … 🤓

1 · Reply

Market Cap	592.57M
Revenue (ttm)	18.14M
Net Income (ttm)	-72.85M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	649,900
Avg Vol	936,122
Day's Range	N/A - N/A
Shares Out	188.72M
Stochastic %K	2%
Beta	1.98
Analysts	Strong Sell
Price Target	$4.50